Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

FDA Warning Letter Cites Violations At Merck Vaccines Plant

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Agency requests meeting with CEO Clark, other senior management to address issues stemming from inspection of Pennsylvania facility.

You may also be interested in...



Merck Plans Gardasil Campaign Targeting “Mid-adult” Women

FDA clears Pennsylvania manufacturing plant; vaccine sBLAs, including one for Gardasil in “older” women, can proceed.

Merck Plans Gardasil Campaign Targeting “Mid-adult” Women

FDA clears Pennsylvania manufacturing plant; vaccine sBLAs, including one for Gardasil in “older” women, can proceed.

Merck Receives FDA “Complete Response” On Gardasil For Women 27-45

Firm also receives complete response to its sBLA for cross-protection.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

UK Parliamentarians Call For A New, Internationally Competitive Pricing System

Keeping Track: Entasis’ Antibiotic Xacduro, Two Opioid Misuse Therapies Clear US FDA; Pfizer’s Paxlovid Makes It Official

One-Page Patient Medication Information Document Moves Forward Under Proposed Rule

Japan Eyes Cutting Reimbursement For COVID-19 Drugs

See All
UsernamePublicRestriction

Register

PS067726

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By